Cookie preferences
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used
Item number | Size | Datasheet | Manual | SDS | Delivery time | Quantity | Price |
---|---|---|---|---|---|---|---|
ELK-ES19996.50 | 50 µl | - | - |
Request delivery time estimate |
169.00€
|
||
ELK-ES19996.100 | 100 µl | - | - |
Request delivery time estimate |
283.00€
|
If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
disease:Defects in F8 are the cause of hemophilia A (HEMA) [MIM:306700]. HEMA is a common... more
Product information "Anti-cleaved-FA8B (Ser760)"
disease:Defects in F8 are the cause of hemophilia A (HEMA) [MIM:306700]. HEMA is a common recessive X-linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal, they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients, F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is non-functional, i.e., the F8C activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.,domain:Domain F5/8 type C 2 is responsible for phospholipid-binding and essential for factor VIII activity.,function:Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.,mass spectrometry:Disulfated PubMed:10368977,mass spectrometry:Monosulfated PubMed:10368977,mass spectrometry:Nonsulfated PubMed:10368977,mass spectrometry:Sulfated PubMed:10368977,mass spectrometry:Trisulfated PubMed:10368977,online information:Factor VIII entry,online information:Factor VIII mutation db,pharmaceutical:Available under the names Kogenate (Bayer) and Recombinate (Baxter and American Home Products). Used to treat hemophilia A.,PTM:Sulfation on Tyr-1699 is essential for binding vWF.,similarity:Belongs to the multicopper oxidase family.,similarity:Contains 1 F5/8 type C domain.,similarity:Contains 2 F5/8 type C domains.,similarity:Contains 3 F5/8 type A domains.,similarity:Contains 6 plastocyanin-like domains.,subunit:Interacts with vWF. vWF binding is essential for the stabilization of F8 in circulation., Protein function: Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa. [The UniProt Consortium] Recommended dilutions: WB 1:1000-2000 ELISA 1:5000-20000. Cellular localization: Secreted, extracellular space.
Keywords: | Anti-cleaved-F8, Anti-cleaved-F8C, FA8B (Cleaved-Ser760) rabbit pAb |
Supplier: | ELK Biotechnology |
Supplier-Nr: | ES19996 |
Properties
Application: | WB, ELISA |
Antibody Type: | Polyclonal |
Conjugate: | No |
Host: | Rabbit |
Species reactivity: | human, mouse |
Immunogen: | Synthesized peptide derived from human FA8B (Cleaved-Ser760) |
MW: | 100 260 kD |
Format: | Purified |
Database Information
KEGG ID : | K03899 | Matching products |
UniProt ID : | P00451 | Matching products |
Gene ID | GeneID 2157 | Matching products |
Handling & Safety
Storage: | -20°C |
Shipping: | +4°C (International: +4°C) |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
Viewed